Advances in the Development of New Drugs and Treatment Targets for Brain Cancers

Dear Colleagues,

Brain cancers represent a significant challenge for current oncology and drug development. Despite being rare in the general population, malignant brain tumors can occur in both adults and children, accounting for up to 33% of cancer-related deaths in children, as an indicator of the severity of these tumors. Standard treatment regimens consist of maximal surgical resection followed by radiotherapy and chemotherapy. However, the main issue with this type of tumor is that they are ‘protected’ by the most impermeable biological barrier—the blood–brain barrier. In addition, the 2021 edition of the WHO Classification of Tumors of the Central Nervous System (CNS) emphasizes the advanced role of molecular diagnostics in the identification of molecular biomarkers, in addition to histologic features in the classification of CNS tumors, in order to improve the newly developed treatments. In recent decades, potent chemotherapeutic agents, oligonucleotides and antibodies for targeted therapy, multifunctional nanomedicines, immunotherapies and cell-based therapies have been developed and proposed to overcome most of the issues that arise due to the location of brain tumors and their biological barriers. This Special Issue invites original research articles and review articles covering new therapeutic strategies and target drugs, exploring the importance of brain tumors at cellular and molecular levels.

Dr. Luis Exequiel Ibarra
Dr. Laura Natalia Milla Sanabria
Dr. Nuria Arias-Ramos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.